Azitra Inc Dossier - Source-backed chat

Azitra Inc

AZTRNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.72

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.14Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $8.3M

Enterprise Value −$1.4M

Shares Outstanding 60.6M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Azitra, Inc. is a clinical-stage precision dermatology biopharmaceutical company that has recently undergone a strategic reorientation to maximize near-term value creation. By leveraging its proprietary microbial genetic engineering platform and a library of approximately 1,500 bacterial strains, the company is expanding beyond high-risk therapeutics into the fast-to-market cosmetic ingredient and biotechnology tools sectors. Backed by a successful $10.5 million financing in March 2026, Azitra is well-positioned to advance its clinical pipeline (ATR-12 and ATR-04) while launching its recombinant filaggrin cosmetic program (ATR-COSF). With multiple high-impact clinical and commercial catalysts expected in the second half of 2026, the stock offers a highly asymmetric risk-reward profile at its current micro-cap valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$0.55

Mean target$0.78

High · most bullish analyst$1.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1015%

The bear case reflects the high-risk nature of early-stage biotech. Clinical readouts for ATR-12 or ATR-04 in H2 2026 show adverse safety events or insufficient therapeutic efficacy, stalling clinical development. Meanwhile, the ATR-COSF cosmetic program fails to show meaningful cosmetic benefits in the Q3 2026 human study, dampening partner interest. With a high cash burn rate and limited cash runway, the company is unable to secure additional non-dilutive or equity financing, leading to severe dilution or a restructuring event.

Base CaseCentral scenario

$0.7860%

Matches the consensus mean

The base case projects steady clinical execution and initial commercial traction. The ATR-12 and ATR-04 trials report positive, well-tolerated safety profiles and encouraging early efficacy signals in H2 2026, keeping both programs on track for subsequent development phases. The ATR-COSF cosmetic program successfully demonstrates skin barrier improvement and reduction in fine lines, allowing Azitra to enter active licensing discussions with cosmetic manufacturers. The company continues to draw on its equity line of credit and existing cash reserves to fund operations into 2027.

Bull CaseUpside scenario

$4.0025%

The bull case assumes rapid clinical success and commercial validation. Topline data from the ATR-12 Phase 1b trial in Netherton syndrome and the ATR-04 Phase 1/2 trial in EGFRi-associated rash (supported by MD Anderson) both deliver outstanding safety and efficacy signals in H2 2026. Concurrently, the ATR-COSF cosmetic program completes its human application study in Q3 2026, leading to a lucrative commercial partnership with a major global skincare brand by early 2027. This dual-track validation triggers significant warrant exercises, injecting up to $21 million in additional capital and eliminating going-concern risks.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Dual-track business model combining high-upside clinical therapeutics with fast-to-market, lower-risk cosmetic ingredients (ATR-COSF).
Proprietary platform featuring a library of ~1,500 unique bacterial strains augmented by artificial intelligence and machine learning.
Strong clinical partnerships, including the addition of MD Anderson Cancer Center as a clinical site for the ATR-04 trial.
Near-term catalysts with multiple topline clinical readouts (ATR-12 and ATR-04) and cosmetic study results expected in H2 2026.

Key Investment Risks

Going concern risk due to a history of operating losses, accumulated deficit of $72.4 million, and cash runway that may not fund operations beyond 12 months without additional capital.
Clinical development risk, where early-stage safety data may not be predictive of broader Phase 2/3 trial outcomes.
High reliance on third-party contract manufacturers for raw materials and active pharmaceutical ingredients.
Extreme stock volatility and potential for heavy dilution from outstanding warrants and equity line of credit draws.

Thesis Invalidation Triggers

Failure of ATR-12 or ATR-04 to meet primary safety and tolerability endpoints in H2 2026 clinical readouts.
Inability to secure a commercial partner or licensing agreement for the ATR-COSF cosmetic ingredient program by mid-2027.
Inability to raise additional capital or trigger warrant exercises, leading to a severe liquidity crisis.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.